|
|
|
|
| Join Outsourced Pharmaceutical Live’s Jeff Buguliskis and panelists on April 22nd at 11 AM Eastern for One Program, Many CDMOs: Managing Multi-Partner Strategies. Registration for this virtual event is free thanks to sponsor Thermo Fisher. |
|
|
|
|
| Mitigating Powder Flow And Static Issues | Case Study | Grace Fine Chemical Manufacturing Services | See how incorporating small amounts of mesoporous silica during micronization can significantly enhance powder flow, thereby making subsequent blending and formulation more consistent. |
|
|
| A Powerful Non-Destructive Tool For Tablet Characterization | White Paper | By Rahul V. Haware, Robert Sedlock, et al., Natoli Engineering Company, Inc. | Assimilate how X-ray micro-CT provides vital, non-destructive analysis of a tablet’s internal 3D physical structure. This structural insight is essential for troubleshooting defects and confirming performance. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Seema Singh of Daiichi Sankyo represents today’s global regulatory leadership in the biopharmaceutical sector. She reflects what the highest expectations should be for all CDMOs, whether your organization is an exacting Japan Pharma, or a start-up biotech in the U.S. Here are her key actions for creating an optimal outsourcing relationship. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| GLP Compliance In A Modern Lab | Article | Dash Bio | GLP compliance isn’t binary. Real defensibility depends on rigorous QA, validated electronic systems, and operational maturity — not just a label. |
|
|
| Reshaping Drug Development With 3D Screen Printing | Q&A | Adare Pharma Solutions | Steven Facer and Laxxon Medical COO Klaus Kühne describe the capabilities of 3D screen printing for pharmaceutical production. Explore prototyping, IP protection, release profile possibilities, and more. |
|
|
|
|
| Outsourced Pharma Capabilities Update | This online event series connects biopharma companies with CDMOs to explore capabilities across biologics production, HPAPI manufacturing, and drug–device combination development. Through concise presentations, CDMOs showcase expertise in development, scale-up, containment, and GMP manufacturing. Attendees gain insights into technologies, regulatory expectations, and partnership models, while engaging directly with providers to evaluate outsourcing options and identify the best-fit partners for advancing and commercializing complex therapies. Click to learn more. |
|
|
|
|
In-Silico Modeling Services | Thermo Fisher Scientific | In silico modeling technologies are transforming drug development and manufacturing by enhancing efficiency, accuracy, to allow innovations. |
|
|
Solid Form Services | Lonza | We have defined work flows to assess and select solid forms in a cost and time efficient manner that meets the needs of each individual program. |
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
